Organogenesis Prepares To Restructure In The Face Of New CMS Skin-Substitute Policy
This article was originally published in The Pink Sheet Daily
The maker of Apligraf for foot ulcers and venous leg ulcers is facing a more than 30% reduction in Medicare reimbursement starting Jan. 1. Organogenesis’ CEO says the firm is readying a plan to significantly trim its business costs so it can continue to market the PMA-approved, bioengineered product.
You may also be interested in...
Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration
Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.
In the final 2014 physician fee schedule rule, CMS scaled back cuts to independent labs from 26 percent to 5 percent. But it moved ahead with its proposal to update individual lab payments based on technological changes, a move that might lead to reductions over the long term.